Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery
Background Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic...
Uložené v:
| Vydané v: | BMC cancer Ročník 12; číslo 1; s. 527 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
16.11.2012
BioMed Central Ltd Springer Nature B.V |
| Predmet: | |
| ISSN: | 1471-2407, 1471-2407 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC).
Methods
Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. ‘Ingenuity Pathway Analysis’ software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS).
Results
Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 – 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 – 1.861)).
Conclusions
Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer.
Trial Registration
Clinical trials.gov NCT00495924 |
|---|---|
| AbstractList | Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC).BACKGROUNDMost cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC).Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS).METHODSNegative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS).Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)).RESULTSUsing stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)).Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer.CONCLUSIONSPancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer.Clinical trials.gov NCT00495924.TRIAL REGISTRATIONClinical trials.gov NCT00495924. Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)). Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Clinical trials.gov NCT00495924. Background: Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Methods: Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Results: Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-[beta]1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-[beta]1 and our cell motility panel (> or = 4 out of 9 genes for DFS and > or = 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)). Conclusions: Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Trial Registration: Clinical trials.gov NCT00495924 Background Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Methods Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Results Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-[beta]1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-[beta]1 and our cell motility panel ([greater than or equai to] 4 out of 9 genes for DFS and [greater than or equai to] 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)). Conclusions Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Trial Registration Clinical trials.gov NCT00495924 Keywords: Circulating tumour cells, Pancreatic ductal adenocarcinoma, Gene expression profiling, p38 - MAPK signaling, Transforming growth factor - [beta]1, Cancer cell migration, Cell motility Background Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Methods Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. ‘Ingenuity Pathway Analysis’ software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Results Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 – 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 – 1.861)). Conclusions Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Trial Registration Clinical trials.gov NCT00495924 Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-[beta]1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-[beta]1 and our cell motility panel ([greater than or equai to] 4 out of 9 genes for DFS and [greater than or equai to] 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)). Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Doc number: 527 Abstract Background: Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs. The aim of the present study was to develop a CTC gene signature and to assess its prognostic relevance after surgery for pancreatic ductal adenocarcinoma (PDAC). Methods: Negative depletion fluorescence activated cell sorting (FACS) was developed and validated with spiking experiments using cancer cell lines in whole human blood samples. This FACS-based method was used to enrich for CTC from the blood of 10 patients who underwent surgery for PDAC. Total RNA was isolated from 4 subgroup samples, i.e. CTC, haematological cells (G), original tumour (T), and non-tumoural pancreatic control tissue (P). After RNA quality control, samples of 6 patients were eligible for further analysis. Whole genome microarray analysis was performed after double linear amplification of RNA. 'Ingenuity Pathway Analysis' software and AmiGO were used for functional data analyses. A CTC gene signature was developed and validated with the nCounter system on expression data of 78 primary PDAC using Cox regression analysis for disease-free (DFS) and overall survival (OS). Results: Using stringent statistical analysis, we retained 8,152 genes to compare expression profiles of CTC vs. other subgroups, and found 1,059 genes to be differentially expressed. The pathway with the highest expression ratio in CTC was p38 mitogen-activated protein kinase (p38 MAPK) signaling, known to be involved in cancer cell migration. In the p38 MAPK pathway, TGF-β1, cPLA2, and MAX were significantly upregulated. In addition, 9 other genes associated with both p38 MAPK signaling and cell motility were overexpressed in CTC. High co-expression of TGF-β1 and our cell motility panel (≥ 4 out of 9 genes for DFS and ≥ 6 out of 9 genes for OS) in primary PDAC was identified as an independent predictor of DFS (p=0.041, HR (95% CI) = 1.885 (1.025 - 3.559)) and OS (p=0.047, HR (95% CI) = 1.366 (1.004 - 1.861)). Conclusions: Pancreatic CTC isolated from blood samples using FACS-based negative depletion, express a cell motility gene signature. Expression of this newly defined cell motility gene signature in the primary tumour can predict survival of patients undergoing surgical resection for pancreatic cancer. Trial Registration: Clinical trials.gov NCT00495924 |
| ArticleNumber | 527 |
| Audience | Academic |
| Author | van Eijsden, Rudy Roskams, Tania Topal, Baki Sergeant, Gregory Van Duppen, Victor |
| AuthorAffiliation | 2 VIB Nucleomics Core, KU Leuven, Herestraat 49, Leuven, 3000, Belgium 1 Department of Abdominal Surgery, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium 4 Laboratory of Experimental Hematology, KU Leuven, Herestraat 49, Leuven, 3000, Belgium 3 Department of Pathology, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium |
| AuthorAffiliation_xml | – name: 2 VIB Nucleomics Core, KU Leuven, Herestraat 49, Leuven, 3000, Belgium – name: 3 Department of Pathology, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium – name: 4 Laboratory of Experimental Hematology, KU Leuven, Herestraat 49, Leuven, 3000, Belgium – name: 1 Department of Abdominal Surgery, University Hospitals Leuven, Herestraat 49, Leuven, 3000, Belgium |
| Author_xml | – sequence: 1 givenname: Gregory surname: Sergeant fullname: Sergeant, Gregory organization: Department of Abdominal Surgery, University Hospitals Leuven – sequence: 2 givenname: Rudy surname: van Eijsden fullname: van Eijsden, Rudy organization: VIB Nucleomics Core, KU Leuven – sequence: 3 givenname: Tania surname: Roskams fullname: Roskams, Tania organization: Department of Pathology, University Hospitals Leuven – sequence: 4 givenname: Victor surname: Van Duppen fullname: Van Duppen, Victor organization: Laboratory of Experimental Hematology, KU Leuven – sequence: 5 givenname: Baki surname: Topal fullname: Topal, Baki email: baki.topal@med.kuleuven.be organization: Department of Abdominal Surgery, University Hospitals Leuven |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23157946$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkslr3DAYxU1JaZb23lMRFEp7mFSStYwvgRC6BAItXc5C1kgeBVmeSvKQ-e_7uZOkM6ELBlv6_HsP6fGOq4M4RFtVzwk-JWQu3hImyYwyLGeEzjiVj6qj-9HBzvqwOs75GmMi53j-pDqkNeGyYeKoWn_W0SSrizfIwNImZHwyY4BJ7FAZ-2GEkQ0hI3uzSjZnpH_tUT8UH3zZoM5Gi7Lvoi5jsqgsdUFALrwpGeUxrf1aB6RdAXPYdjZtnlaPnQ7ZPrv9nlTf37_7dvFxdvXpw-XF-dXMiJoUeEs217UQhhhGJWNiYY2TpLVEG9e2TDhhNFCicVTWhOoWU-fglrwVAjf1SXW29V2NbW8XxsaSdFCr5HudNmrQXu3_iX6pumGtat40uJFg8PrWIA0_RpuL6n2erq-jHcasCONzTpua4f-jNcTPBOEM0JcP0GuIOUISE8WJlFSQ31Sng1U-ugGOaCZTdc5rRjhvagHU6R8oeBa29wb64jzM9wRv9gTAFHtTOj3mrC6_ftlnX-2wS6tDWeYhjMUPMe-DL3aDvk_4rmkAiC1g0pBzsk4ZX_TkA8f1QRGspkqrqbNq6qwiVEGlQYgfCO-8_yEhW0kGNELfduL9m-YnIHIF2g |
| CitedBy_id | crossref_primary_10_1371_journal_pone_0219566 crossref_primary_10_1371_journal_pone_0133562 crossref_primary_10_1371_journal_pone_0138810 crossref_primary_10_3389_fcell_2021_748631 crossref_primary_10_1158_0008_5472_CAN_15_0145 crossref_primary_10_3390_ijms20194894 crossref_primary_10_1155_2020_7938280 crossref_primary_10_1126_science_1244270 crossref_primary_10_7314_APJCP_2014_15_15_6015 crossref_primary_10_1016_j_bbcan_2018_02_001 crossref_primary_10_1158_0008_5472_CAN_18_0540 crossref_primary_10_3389_fgene_2021_663787 crossref_primary_10_3390_ijms21051872 crossref_primary_10_3389_fonc_2019_00874 crossref_primary_10_1002_ijc_29070 crossref_primary_10_1016_j_mam_2013_08_001 crossref_primary_10_1016_j_cca_2014_02_019 crossref_primary_10_1002_ctd2_248 crossref_primary_10_1159_000360983 crossref_primary_10_1186_s12916_017_0936_z crossref_primary_10_3390_cancers6010595 crossref_primary_10_3390_ijms20133204 crossref_primary_10_3390_ijms22189818 crossref_primary_10_3892_ol_2016_5432 crossref_primary_10_1038_s41598_023_34317_2 crossref_primary_10_1158_1078_0432_CCR_20_1359 crossref_primary_10_1186_s12967_023_03874_5 crossref_primary_10_1080_21541248_2017_1337545 crossref_primary_10_1097_SLA_0000000000003035 crossref_primary_10_1007_s10620_014_3033_6 crossref_primary_10_1038_srep43710 crossref_primary_10_1038_s41598_020_71181_w crossref_primary_10_3892_ijo_2016_3389 crossref_primary_10_3390_cancers13030485 crossref_primary_10_1053_j_gastro_2016_05_052 crossref_primary_10_1007_s10555_019_09795_4 crossref_primary_10_1007_s13277_014_2716_0 crossref_primary_10_1093_bib_bby023 crossref_primary_10_1038_s41698_024_00562_5 crossref_primary_10_2147_OTT_S496228 |
| Cites_doi | 10.1091/mbc.E08-09-0898 10.1038/nm1469 10.1189/jlb.1008647 10.1093/bioinformatics/btn615 10.1038/ncb1507 10.1093/bioinformatics/btg405 10.1038/nrclinonc.2009.23 10.1007/978-3-642-59349-9_13 10.1002/ijc.2910150505 10.1038/ng1215 10.1111/j.1749-6632.2009.04911.x 10.1038/nbt1385 10.1186/gb-2004-5-10-r80 10.1038/nrc1275 10.1016/S0092-8674(00)81683-9 10.1038/ncb1973 10.1002/cyto.10161 10.1002/jcp.21783 10.1111/j.2517-6161.1995.tb02031.x 10.2202/1544-6115.1027 10.2144/03356rr01 |
| ContentType | Journal Article |
| Copyright | Sergeant et al; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. COPYRIGHT 2012 BioMed Central Ltd. 2012 Sergeant et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Copyright ©2012 Sergeant et al; licensee BioMed Central Ltd. 2012 Sergeant et al; licensee BioMed Central Ltd. |
| Copyright_xml | – notice: Sergeant et al; licensee BioMed Central Ltd. 2012 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: COPYRIGHT 2012 BioMed Central Ltd. – notice: 2012 Sergeant et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. – notice: Copyright ©2012 Sergeant et al; licensee BioMed Central Ltd. 2012 Sergeant et al; licensee BioMed Central Ltd. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM ISR 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 8FD FR3 P64 RC3 5PM |
| DOI | 10.1186/1471-2407-12-527 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Science ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts Genetics Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic Genetics Abstracts Engineering Research Database Technology Research Database Biotechnology and BioEngineering Abstracts |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Genetics Abstracts Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2407 |
| EndPage | 527 |
| ExternalDocumentID | PMC3599097 2911024291 A534155936 23157946 10_1186_1471_2407_12_527 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- 0R~ 23N 2VQ 2WC 4.4 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHSBF AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HMCUK HYE IAO IHR IHW INH INR IPNFZ ISR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RIG RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS U2A UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 3V. 7TO 7XB 8FK AZQEC DWQXO H94 K9. PKEHL PQEST PQUKI PRINS 7X8 8FD FR3 P64 RC3 5PM |
| ID | FETCH-LOGICAL-c631t-c6748a366c1c427446decf71be1acfbb46f6cac6769f27312ab02ff7805b66093 |
| IEDL.DBID | BENPR |
| ISICitedReferencesCount | 47 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000316188200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2407 |
| IngestDate | Tue Nov 04 02:02:39 EST 2025 Tue Oct 21 13:21:29 EDT 2025 Sun Nov 09 13:18:16 EST 2025 Mon Oct 06 18:33:57 EDT 2025 Tue Nov 11 10:56:52 EST 2025 Tue Nov 04 18:17:09 EST 2025 Thu Nov 13 16:45:19 EST 2025 Thu May 22 21:24:11 EDT 2025 Thu Apr 03 07:02:20 EDT 2025 Sat Nov 29 04:29:20 EST 2025 Tue Nov 18 21:42:57 EST 2025 Sat Sep 06 07:24:38 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cell motility Transforming growth factor - β1 Gene expression profiling Pancreatic ductal adenocarcinoma p38 – MAPK signaling Circulating tumour cells Cancer cell migration |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c631t-c6748a366c1c427446decf71be1acfbb46f6cac6769f27312ab02ff7805b66093 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Article-2 ObjectType-Feature-1 |
| OpenAccessLink | https://www.proquest.com/docview/1315177261?pq-origsite=%requestingapplication% |
| PMID | 23157946 |
| PQID | 1315177261 |
| PQPubID | 44074 |
| PageCount | 1 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3599097 proquest_miscellaneous_1458529340 proquest_miscellaneous_1317846154 proquest_journals_1315177261 gale_infotracmisc_A534155936 gale_infotracacademiconefile_A534155936 gale_incontextgauss_ISR_A534155936 gale_healthsolutions_A534155936 pubmed_primary_23157946 crossref_citationtrail_10_1186_1471_2407_12_527 crossref_primary_10_1186_1471_2407_12_527 springer_journals_10_1186_1471_2407_12_527 |
| PublicationCentury | 2000 |
| PublicationDate | 2012-11-16 |
| PublicationDateYYYYMMDD | 2012-11-16 |
| PublicationDate_xml | – month: 11 year: 2012 text: 2012-11-16 day: 16 |
| PublicationDecade | 2010 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC cancer |
| PublicationTitleAbbrev | BMC Cancer |
| PublicationTitleAlternate | BMC Cancer |
| PublicationYear | 2012 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V |
| References | Gertler, Rosenberg, Fuehrer, Dahm, Nekarda, Siewert (CR3) 2003; 162 Ehrchen, Sunderkotter, Foell, Vogl, Roth (CR15) 2009; 86 Zuo, Chen (CR16) 2009; 20 Hanahan, Weinberg (CR1) 2000; 100 Carbon, Ireland, Mungall, Shu, Marshall, Lewis (CR11) 2009; 25 Gentleman, Carey, Bates, Bolstad, Dettling, Dudoit, Ellis, Gautier, Ge, Gentry (CR7) 2004; 5 Chuang, Yang, Chen, Huang, Tan, Lin, Hsu, Fong, Tang (CR18) 2009; 220 Yu, Jove (CR19) 2004; 4 Pantel, Riethdorf (CR2) 2009; 6 Gautier, Cope, Bolstad, Irizarry (CR6) 2004; 20 CR9 Geiss, Bumgarner, Birditt, Dahl, Dowidar, Dunaway, Fell, Ferree, George, Grogan, James, Maysuria, Mitton, Oliveri, Osborn, Peng, Ratcliffe, Webster, Davidson, Hood, Dimitrov (CR22) 2008; 26 Schoor, Weinschenk, Hennenlotter, Corvin, Stenzl, Rammensee, Stevanovic (CR13) 2003; 35 Aggarwal, Kunnumakkara, Harikumar, Gupta, Tharakan, Koca, Dey, Sung (CR20) 2009; 1171 Lieber, Mazzetta, Nelson-Rees, Kaplan, Todaro (CR5) 1975; 15 Hiratsuka, Watanabe, Aburatani, Maru (CR14) 2006; 8 Giampieri, Manning, Hooper, Jones, Hill, Sahai (CR17) 2009; 11 Albertson, Collins, McCormick, Gray (CR12) 2003; 34 Smyth (CR8) 2004; 3 Benjamini, Hochberg (CR10) 1995; 57 Steeg (CR21) 2006; 12 Rosenberg, Gertler, Friederichs, Fuehrer, Dahm, Phelps, Thorban, Nekarda, Siewert (CR4) 2002; 49 BB Aggarwal (3727_CR20) 2009; 1171 GK Smyth (3727_CR8) 2004; 3 W Zuo (3727_CR16) 2009; 20 R Rosenberg (3727_CR4) 2002; 49 S Hiratsuka (3727_CR14) 2006; 8 O Schoor (3727_CR13) 2003; 35 RC Gentleman (3727_CR7) 2004; 5 S Giampieri (3727_CR17) 2009; 11 3727_CR9 Y Benjamini (3727_CR10) 1995; 57 D Hanahan (3727_CR1) 2000; 100 H Yu (3727_CR19) 2004; 4 R Gertler (3727_CR3) 2003; 162 K Pantel (3727_CR2) 2009; 6 PS Steeg (3727_CR21) 2006; 12 DG Albertson (3727_CR12) 2003; 34 L Gautier (3727_CR6) 2004; 20 JM Ehrchen (3727_CR15) 2009; 86 JY Chuang (3727_CR18) 2009; 220 M Lieber (3727_CR5) 1975; 15 GK Geiss (3727_CR22) 2008; 26 S Carbon (3727_CR11) 2009; 25 |
| References_xml | – volume: 20 start-page: 1020 year: 2009 end-page: 1029 ident: CR16 article-title: Specific activation of mitogen-activated protein kinase by transforming growth factor-beta receptors in lipid rafts is required for epithelial cell plasticity publication-title: Mol Biol Cell doi: 10.1091/mbc.E08-09-0898 – volume: 12 start-page: 895 year: 2006 end-page: 904 ident: CR21 article-title: Tumour metastasis: mechanistic insights and clinical challenges publication-title: Nat Med doi: 10.1038/nm1469 – volume: 86 start-page: 557 year: 2009 end-page: 566 ident: CR15 article-title: The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer publication-title: J Leukoc Biol doi: 10.1189/jlb.1008647 – volume: 25 start-page: 288 year: 2009 end-page: 289 ident: CR11 article-title: AmiGO: online access to ontology and annotation data publication-title: Bioinformatics doi: 10.1093/bioinformatics/btn615 – volume: 8 start-page: 1369 year: 2006 end-page: 1375 ident: CR14 article-title: Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis publication-title: Nat Cell Biol doi: 10.1038/ncb1507 – volume: 20 start-page: 307 year: 2004 end-page: 315 ident: CR6 article-title: affy--analysis of Affymetrix GeneChip data at the probe level publication-title: Bioinformatics doi: 10.1093/bioinformatics/btg405 – ident: CR9 – volume: 6 start-page: 190 year: 2009 end-page: 191 ident: CR2 article-title: Pathology: are circulating tumour cells predictive of overall survival? publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2009.23 – volume: 162 start-page: 149 year: 2003 end-page: 155 ident: CR3 article-title: Detection of circulating tumour cells in blood using an optimized density gradient centrifugation publication-title: Recent Results Cancer Res doi: 10.1007/978-3-642-59349-9_13 – volume: 15 start-page: 741 year: 1975 end-page: 747 ident: CR5 article-title: Establishment of a continuous tumour-cell line (panc-1) from a human carcinoma of the exocrine pancreas publication-title: Int J Cancer doi: 10.1002/ijc.2910150505 – volume: 3 start-page: Article3 year: 2004 ident: CR8 article-title: Linear models and empirical bayes methods for assessing differential expression in microarray experiments publication-title: Stat Appl Genet Mol Biol – volume: 57 start-page: 289 year: 1995 end-page: 300 ident: CR10 article-title: Controlling the false discovery rate: a practical and powerful approach to multiple testing publication-title: J R Stat Soc Ser B – volume: 34 start-page: 369 year: 2003 end-page: 376 ident: CR12 article-title: Chromosome aberrations in solid tumours publication-title: Nat Genet doi: 10.1038/ng1215 – volume: 35 start-page: 1192 year: 2003 end-page: 1196 ident: CR13 article-title: Moderate degradation does not preclude microarray analysis of small amounts of RNA publication-title: Biotechniques – volume: 1171 start-page: 59 year: 2009 end-page: 76 ident: CR20 article-title: Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship? publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.04911.x – volume: 26 start-page: 317 year: 2008 end-page: 325 ident: CR22 article-title: Direct multiplexed measurement of gene expression with color-coded probe pairs publication-title: Nat Biotechnol doi: 10.1038/nbt1385 – volume: 5 start-page: R80 year: 2004 ident: CR7 article-title: Bioconductor: open software development for computational biology and bioinformatics publication-title: Genome Biol doi: 10.1186/gb-2004-5-10-r80 – volume: 4 start-page: 97 year: 2004 end-page: 105 ident: CR19 article-title: The STATs of cancer–new molecular targets come of age publication-title: Nat Rev Cancer doi: 10.1038/nrc1275 – volume: 100 start-page: 57 year: 2000 end-page: 70 ident: CR1 article-title: The hallmarks of cancer publication-title: Cell doi: 10.1016/S0092-8674(00)81683-9 – volume: 11 start-page: 1287 year: 2009 end-page: 1296 ident: CR17 article-title: Localized and reversible TGFbeta signalling switches breast cancer cells from cohesive to single cell motility publication-title: Nat Cell Biol doi: 10.1038/ncb1973 – volume: 49 start-page: 150 year: 2002 end-page: 158 ident: CR4 article-title: Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumour cells in blood publication-title: Cytometry doi: 10.1002/cyto.10161 – volume: 220 start-page: 418 year: 2009 end-page: 426 ident: CR18 article-title: CCL5/CCR5 axis promotes the motility of human oral cancer cells publication-title: J Cell Physiol doi: 10.1002/jcp.21783 – volume: 20 start-page: 307 year: 2004 ident: 3727_CR6 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btg405 – volume: 8 start-page: 1369 year: 2006 ident: 3727_CR14 publication-title: Nat Cell Biol doi: 10.1038/ncb1507 – volume: 4 start-page: 97 year: 2004 ident: 3727_CR19 publication-title: Nat Rev Cancer doi: 10.1038/nrc1275 – volume: 12 start-page: 895 year: 2006 ident: 3727_CR21 publication-title: Nat Med doi: 10.1038/nm1469 – volume: 34 start-page: 369 year: 2003 ident: 3727_CR12 publication-title: Nat Genet doi: 10.1038/ng1215 – volume: 220 start-page: 418 year: 2009 ident: 3727_CR18 publication-title: J Cell Physiol doi: 10.1002/jcp.21783 – volume: 100 start-page: 57 year: 2000 ident: 3727_CR1 publication-title: Cell doi: 10.1016/S0092-8674(00)81683-9 – volume: 57 start-page: 289 year: 1995 ident: 3727_CR10 publication-title: J R Stat Soc Ser B doi: 10.1111/j.2517-6161.1995.tb02031.x – volume: 5 start-page: R80 year: 2004 ident: 3727_CR7 publication-title: Genome Biol doi: 10.1186/gb-2004-5-10-r80 – volume: 3 start-page: Article3 year: 2004 ident: 3727_CR8 publication-title: Stat Appl Genet Mol Biol doi: 10.2202/1544-6115.1027 – volume: 35 start-page: 1192 year: 2003 ident: 3727_CR13 publication-title: Biotechniques doi: 10.2144/03356rr01 – volume: 6 start-page: 190 year: 2009 ident: 3727_CR2 publication-title: Nat Rev Clin Oncol doi: 10.1038/nrclinonc.2009.23 – volume: 26 start-page: 317 year: 2008 ident: 3727_CR22 publication-title: Nat Biotechnol doi: 10.1038/nbt1385 – volume: 1171 start-page: 59 year: 2009 ident: 3727_CR20 publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2009.04911.x – volume: 162 start-page: 149 year: 2003 ident: 3727_CR3 publication-title: Recent Results Cancer Res doi: 10.1007/978-3-642-59349-9_13 – volume: 25 start-page: 288 year: 2009 ident: 3727_CR11 publication-title: Bioinformatics doi: 10.1093/bioinformatics/btn615 – volume: 86 start-page: 557 year: 2009 ident: 3727_CR15 publication-title: J Leukoc Biol doi: 10.1189/jlb.1008647 – volume: 49 start-page: 150 year: 2002 ident: 3727_CR4 publication-title: Cytometry doi: 10.1002/cyto.10161 – volume: 15 start-page: 741 year: 1975 ident: 3727_CR5 publication-title: Int J Cancer doi: 10.1002/ijc.2910150505 – ident: 3727_CR9 – volume: 11 start-page: 1287 year: 2009 ident: 3727_CR17 publication-title: Nat Cell Biol doi: 10.1038/ncb1973 – volume: 20 start-page: 1020 year: 2009 ident: 3727_CR16 publication-title: Mol Biol Cell doi: 10.1091/mbc.E08-09-0898 |
| SSID | ssj0017808 |
| Score | 2.2722466 |
| Snippet | Background
Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant... Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant organs.... Background Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in distant... Doc number: 527 Abstract Background: Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary... Background: Most cancer deaths are caused by metastases, resulting from circulating tumor cells (CTC) that detach from the primary cancer and survive in... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 527 |
| SubjectTerms | Adenocarcinoma - diagnosis Adenocarcinoma - metabolism Adenocarcinoma - mortality Adenocarcinoma - surgery Aged Analysis Biomarkers, Tumor - metabolism Biomedical and Life Sciences Biomedicine Bone morphogenetic proteins Cancer Cancer Research Cancer therapies Carcinoma, Pancreatic Ductal - diagnosis Carcinoma, Pancreatic Ductal - genetics Carcinoma, Pancreatic Ductal - mortality Carcinoma, Pancreatic Ductal - surgery Care and treatment Cell Line, Tumor DNA microarrays Female Fluorescence Gene expression Gene Expression Profiling Genes Genetic aspects Genomics Health Promotion and Disease Prevention Hematology Humans Information management Male Medical research Medicine/Public Health Metastasis Microarray Analysis Middle Aged Mitogens Motility Neoplastic Cells, Circulating - metabolism Oncology Oncology, Experimental Pancreas Pancreatic cancer Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - genetics Pancreatic Neoplasms - mortality Pancreatic Neoplasms - surgery Patient outcomes Predictive Value of Tests Prognosis Protein kinases Proteins Research Article RNA Statistical analysis Surgery Surgical Oncology Survival Analysis Transforming growth factors Translational oncology |
| SummonAdditionalLinks | – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3daxQxEB9qFfHF74_VqlEEsXD0sptNdh-LWPTBUlqVvoUkl7QHuie3u8U_35nsB91DC_pysOSXu-xkJvnlZjID8Ebkfu6tdTOujKWk2m5mvDBo8UUWVBCFsItYbEIdHhanp-XRFqTDXZgY7T64JONKHc26kHscl1HyBaiYvT9V1-A6bnYFGePxybfRc6CKeTG4I__Qa7L9bC7Cl3ahzQjJDTdp3H0O7vzPuO_C7Z5rsv1OOe7Blq_uw83PvTf9AVwc4ZRH0uiYo9lfM7dcu1jQqzpjTfsDv4HRX_s1879ixCwz8ZlRCB8ReIb65xkFgcQEoaw5Nw1DJP5EU7O6xYUIVZnFSuT0SFewH8LXgw9f3n-c9XUYZk5mvMFPJQqTSem4E5RRUC68C4pbz40L1goZpDOOgmUDsiGeGjtPQ6BqCVbKeZk9gu1qVfknwLgMxohgVShLkS6EsUGphbUF0iabO5XA3jA92vVJyqlWxncdDyuF1CROTeLUPNUozgTejT1-dgk6rsC-pBnX3RXT0bb1fp4RryozmcDriKDMGBWF3pyZtq71p5PjCehtDworHBy-eneTAV-RkmlNkDsTJJqumzYPqqf7paPWPEMShmceyRN4NTZTTwqHq_yqjRiFxBHp7xUYgSdBJHNinsDjTptHASGpz6myQAJqoucjgJKOT1uq5XlMPp7lyF9KFOXuoO2Xhv4XuT_9F_AzuIWkNKX7nlzuwHazbv1zuOEummW9fhGN_TemAVGP priority: 102 providerName: Springer Nature |
| Title | Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery |
| URI | https://link.springer.com/article/10.1186/1471-2407-12-527 https://www.ncbi.nlm.nih.gov/pubmed/23157946 https://www.proquest.com/docview/1315177261 https://www.proquest.com/docview/1317846154 https://www.proquest.com/docview/1458529340 https://pubmed.ncbi.nlm.nih.gov/PMC3599097 |
| Volume | 12 |
| WOSCitedRecordID | wos000316188200001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: BioMedCentral customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: Springer Nature Consortium list (Orbis Cascade Alliance) customDbUrl: eissn: 1471-2407 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017808 issn: 1471-2407 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYhxAvfH8ERjEICYFUtW5cO3lCA21iD6uqDlB5smzH3ipt6WiSiT-fOzcNTSX6wksky5cP2-fzL77z_Qh5x0du4IyxPSa1waTatqcd1zDjk9hLzxNuskA2IcfjZDZLJ_WGW1GHVa5tYjDU2cLiHnmfxbA2ARQU7NP1rx6yRqF3tabQ2CP7mKmMd8j-56PxZNr4EWQySNbOyUT0GZhi9CfIwACATDIbi9G2Sd5Yk7bjJbecpmEtOr7_v614QO7VKJQertTmIbnl8kfkzmntZ39MbiagDAFOWmpRL5bUzpc2UH3l57SsruAJFDf9C-p-h1haqkOZYnAfQnsKmukohoeE1KG0vNAlBUl4RVnQogITBUpOA0c5FvFw9hPy_fjo25evvZqhoWdFzEq4Sp7oWAjLLMdcgyJz1ktmHNPWG8OFF1ZbDKP1gJPYUJvB0HvkUTBCDNL4Kenki9w9J5QJrzX3Rvo05cOMa-OlzIxJAFCZkZUR6a-HStk6fTmyaFyq8BuTCIWDq3BwFRsqGNyIfGjuuF6l7tgh-xpHX60OnzazXh2OYkRcaSwi8jZIYM6MHINyznVVFOrkbNoSel8L-QV8HDR9dcYBmohptlqSBy1JmNS2Xb3WH1UblUL9VZ6IvGmq8U4MlMvdogoyEiAlAOMdMhz-EQHm8UFEnq00u-kggPsj5ByIiGzpfCOA6cjbNfn8IqQlj0eAbFLoyo_r2bHx6f_o9xe72_mS3AWAOsSzn0wckE65rNwrctvelPNi2SV7cibDNenWE78b9lSgNDk5nfyE0vTsxx9ANmQ3 |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLamgYAX7pfAYAaBEEhV68S10weEJmBata2aYEh9M7Zrb5UgHU064E_xGznHudBUom974KVS5C9t7J5rfPwdQp7zvus5Y2yHSW2QVNt2tOMaND5NvPQ85WYSmk3I0SgdjwdHG-R3fRYGyyprmxgM9WRm8R15lyXgmyAUFOzt2fcOdo3C3dW6hUYpFvvu1w9I2fI3w_fw_76I490Px-_2OlVXgY4VCSvgU_JUJ0JYZjny44mJs14y45i23hguvLDaYumnB9_OYm16sffI_W-ECORLYPIvgR2XWEImx02CxwCT1luhqegyMPy4eyFDvwHsW7Pk-lYdwJIHXK3OXNmiDZ5v98b_tmY3yfUqxqY7pVLcIhsuu02uHFZVBHfI-RGIegiWLbUo9XNqp3MbGpllJ7RYfINvoLilkVP3M1QKUx2uKZYuYuJCQe8cxeKXQIxKi1NdUEDCTxQ5zRdggEGFaejAjpd49Pwu-Xwhs75HNrNZ5h4QyoTXmnsj_WDA4wnXxks5MSaFcNH0rYxItxYNZStyduwR8lWFJC0VCoVJoTApFisQpoi8au44K4lJ1mC3UdpUebS2sWlqp59gPDlIRESeBQQygmRYcnSiF3muhp8-tkAvK5CfwcPB1MsTHDBFJBFrIbdaSDBZtj1cy6uqTGau_gprRJ42w3gnlgFmbrYIGAkBM4T9azAcMmAIYnkvIvdLTWoWCJKZPnZUiIhs6VgDQLL19kg2PQ2k60kf4rYBLOXrWhuXHv0f6_5w_Ty3ydW948MDdTAc7T8i1yAUj_GUKxNbZLOYL9xjctmeF9N8_iSYGUq-XLSO_gF2Hrp4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3di9QwEA96yuGL3x_V04siiMKyTZsm7eOhLh7qsngq9xaSbHK3oN1j2x7--c6kH1wXPRBfFkom3WY6SX7pzPyGkJc8c7Ezxk6Y1AZJte1EO65hxuepl57n3CxDsQk5n-fHx8Wi--BW9dHuvUuyzWlAlqaynp4tfTvFczFlsKSiX0AGJv9EXiXXOJYMwtP60ffBiyDzOO9dk3_oNdqKthfkCzvSdrTklss07ESzW_87htvkZodB6UFrNHfIFVfeJbufOy_7PXK-AFMIYNJSi1axoXa1saHQV3lC6-Yn3IHiJ_-Kul8hkpbqcE0xtA-BPQW7dBSDQwJxKK1PdU1BEv6irmjVwAIFJk5DhXK8xNTs--Tb7P3Xtx8mXX2GiRUpq-FX8lynQlhmOTINiqWzXjLjmLbeGC68sNpiEK0HlMQSbeLEe6yiYISIi_QB2SnXpXtEKBNea-6N9EXBkyXXxku5NCYHOGUyKyMy7V-Vsh15OdbQ-KHCISYXCtWpUJ2KJQrUGZHXQ4-zlrjjEtl9fPuqTT0d5rw6yFLEW0UqIvIiSCBjRokhOSe6qSp1ePRlJPSqE_JreDgYepvhAENEkq2R5N5IEqa0HTf3Zqi6JaVSLAVwBmchwSLyfGjGnhgmV7p1E2QkAEqAxZfIcDghAsjjcUQetpY9KAjAfoYVByIiRzY_CCAZ-bilXJ0GUvI0A1xTgCrf9JZ_4dH_ovfH_yK8T3YX72bq0-H84xNyA3BrgimhTOyRnXrTuKfkuj2vV9XmWVgDfgOliV1X |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pancreatic+cancer+circulating+tumour+cells+express+a+cell+motility+gene+signature+that+predicts+survival+after+surgery&rft.jtitle=BMC+cancer&rft.au=Sergeant%2C+Gregory&rft.au=van+Eijsden%2C+Rudy&rft.au=Roskams%2C+Tania&rft.au=Van+Duppen%2C+Victor&rft.date=2012-11-16&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2407&rft.eissn=1471-2407&rft.volume=12&rft_id=info:doi/10.1186%2F1471-2407-12-527&rft.externalDBID=ISR&rft.externalDocID=A534155936 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2407&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2407&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2407&client=summon |